Pharma Mar SA PHM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- €65.90
- Day Range
- €64.15–66.20
- 52-Week Range
- €62.00–105.20
- Bid/Ask
- €65.35 / €66.95
- Shares Outstanding
- 17.25M
- Market Cap
- €1.13B
- Volume/Avg
- 39,477 / 34,687
Key Statistics
- Price/Earnings (Normalized)
- 17.00
- Price/Sales
- 4.11
- Dividend Yield (Trailing)
- 1.53%
- Dividend Yield (Forward)
- 1.53%
- Dividend Payment Schedule
- Jul
- Total Yield
- 2.67%
Company Profile
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 505
- Website
- http://www.pharmamar.com
Valuation
Metric | PHM |
|---|---|
Price/Earnings (Normalized) | 17.00 |
Price/Book Value | 4.76 |
Price/Sales | 4.11 |
Price/Cash Flow | 14.02 |
Price/Earnings
PHM
Financial Strength
Metric | PHM |
|---|---|
Quick Ratio | 1.83 |
Current Ratio | 2.36 |
Interest Coverage | — |
Quick Ratio
PHM
Profitability
Metric | PHM |
|---|---|
Return on Assets (Normalized) | 16.56% |
Return on Equity (Normalized) | 26.85% |
Return on Invested Capital (Normalized) | 21.38% |
Return on Assets
PHM
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|@#%Zp>^ | LOCK|n<<Q | $139B | |||
| Moderna Inc MRNA | LOCK|>Wd%B^x | LOCK|#?B | $103B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|qpr$#& | LOCK|c&?& | $94B | |||
| argenx SE ADR ARGX | LOCK|^Pz<NVb | LOCK|yM$ | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|?PTW%r | LOCK|$# | $47B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|jPbljGd | LOCK|kC&^ | $30B | |||
| Incyte Corp INCY | LOCK|<Mz#^j | LOCK|^W | $24B | |||
| BioNTech SE ADR BNTX | LOCK|t^$Nrh | LOCK|<@V | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|J@^<bX# | LOCK|>Gg! | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|>T%dyM | LOCK|fd | $15B |
United States